Clinical trial · Interventional
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Potential Utility of Peroxisome Proliferator-activated Receptor Gamma Agonists in the Eradication of Chronic Myeloid Leukemia Stem Cells: Myth or Truth?
NCT04883125CI-TRIAL-00051755completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding pioglitazone to imatinib therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myelogenous Leukemia, BCR-ABL Positive | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
| CML, Chronic Phase | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pioglitazone 15mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Interventional no
- description
- Patients treated with both drugs ( imatinib and pioglitazone)
- interventionNames
- Drug: Pioglitazone 15mg
- type
- NO_INTERVENTION
- label
- Control
- description
- Historical control (treated with imatinib only)
Primary outcomes (2)
- measure
- Rate of major molecular response(MMR) at 12 months
- timeFrame
- 1 year
- description
- Percentage of patients obtaining MMR at 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * CML cases (BCR-ABL1 positive) Exclusion Criteria: * Accelerated or blastic crisis * Atypical CML (BCR-ABL1 negative) * Chronic myelomonocytic leukemia (CMML) * Pregnant or breastfeeding females. * Patients with severe organ dysfunction
References
Publications (1)
- DERIVEDAtef B, El-Ashwah S, Saleh LM, Gawish H, Mabed M. Potential utility of PPARgamma agonists in targeting chronic myeloid leukemia stem cells. Ann Hematol. 2026 Feb 25;105(4):136. doi: 10.1007/s00277-026-06795-7. PMID 41735647